Skip to main content
Epocrates Online
Contact us
Explore features
Reach clinicians
Buy now
By
vgreene
, 29 March, 2021
Other considerations2
By
vgreene
, 29 March, 2021
Duration extended 3 4 unless uarr bleeding risk and clot not CA assoc
By
vgreene
, 29 March, 2021
Range 2 0 3 0
By
vgreene
, 29 March, 2021
Target INR 2 5
By
vgreene
, 29 March, 2021
Tx recommendations1 4
By
vgreene
, 29 March, 2021
Related resource epocrates Venous Thromboembolism Tx Guideline Synthesis
By
vgreene
, 29 March, 2021
Consider switch to LMWH if recurrence while on therapeutic VKA
By
vgreene
, 29 March, 2021
Other considerations1 4
By
vgreene
, 29 March, 2021
Duration lifetime 3 4 unless pt high risk for bleeding clot not CA assoc
By
vgreene
, 29 March, 2021
Range 2 0 3 0
Pagination
First page
Previous page
…
Page
1116
Page
1117
Page
1118
Page
1119
Current page
1120
Page
1121
Page
1122
Page
1123
Page
1124
…
Next page
Last page
About Us
Company Overview
Media Relations
Contact
Editorial Policy
Editorial Process
Third-Party Sponsorship Policy
athenahealth
Products
Core Products
Mobile CME
Product Licenses
Business Solutions
Pharma
Market Research
Institutions
Support
Support Center
Install
My Account
Stay Connected
Facebook
Twitter
YouTube
